trial · primary record
PVX-108
Peanut Allergy
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 95 |
| Primary completion | 2028-06 |
| Primary endpoint | Ratio of maximum tolerated dose (MTD) of peanut protein at the Week 46 double blind placebo-controlled food challenge (DBPCFC) relative to baseline in children aged 4 to 11 years treated with PVX108 compared to placebo |
| Registry ID | NCT05621317 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:24.008Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05621317
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.